Canada markets closed

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7820-0.0140 (-1.76%)
At close: 04:00PM EDT
0.7403 -0.04 (-5.33%)
After hours: 04:39PM EDT

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees231

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.Co-Founder, President, CEO & Director1.01MN/A1966
Mr. Erin E. Jones M.S.Executive VP & COO689.87kN/A1972
Dr. Karin Jooss Ph.D.Executive VP and Head of Research & Development748.2kN/A1965
Ms. Vassiliki EconomidesExecutive VP & CFON/AN/A1980
Mr. James ChoChief Accounting OfficerN/AN/AN/A
Mr. George E. MacDougallDirector of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Stacy ProctorExecutive VP & Chief People OfficerN/AN/AN/A
Dr. Matthew J. Hawryluk M.B.A., Ph.D.Executive VP & Chief Business OfficerN/AN/A1978
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone bio, Inc.’s ISS Governance QualityScore as of June 1, 2024 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.